Loren Berry - Concepedia

Concepedia

Author

Loren Berry

Amgen (United States)

Also Known As

Berry, Loren M., L. M. Berry, L.M. Berry, Loren Berry, Loren M Berry, Loren M. Berry

35

Publications

1.4K

Citations

19

H-Index

53

Concepts

All Affiliations

Amgen (United States)McLean Hospital Harvard University Pfizer (United States)

LB

About

Loren Berry is an author at Amgen (United States) specializing in medicine, pharmacology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	680
2	Natural Sciences	9	9	550
3	Health Sciences	1	1	11
4	Social Sciences	1	1	107
5	Allergy	1	1	12

Loren Berry

×

23

Publications

1.4K

Citations

19

H-Index

	Year	Citations
Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase Brian K. Albrecht, Jean-Christophe Harmange, David Bauer, Journal of Medicinal Chemistry Combinatorial ChemistryChemoprevention StrategySelective InhibitorsCancer BiologyPharmaceutical Chemistry	2008	138
Esterase Activities in the Blood, Liver and Intestine of Several Preclinical Species and Humans Loren Berry, Lance Wollenberg, Zhiyang Zhao Drug Metabolism Letters Medicinal ChemistryBiosynthesisTissue DifferencesPharmacological StudyBiochemistry	2009	111
An Examination of IC50 and IC50-Shift Experiments in Assessing Time-Dependent Inhibition of CYP3A4, CYP2D6 and CYP2C9 in Human Liver Microsomes Loren Berry, Zhiyang Zhao Drug Metabolism Letters	2008	107
Sex Differences in Sensitivity to the Depressive-like Effects of the Kappa Opioid Receptor Agonist U-50488 in Rats Shayla Russell, Anna B. Rachlin, Karen L. Smith, Biological Psychiatry PsychiatryBehavioral NeuroscienceAddictionMedicineSex Differences	2013	107
Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-<i>N</i>-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1<i>H</i>-pyrazole-4-carboxamide (AMG 458) Longbin Liu, Aaron Siegmund, Ning Xi, Journal of Medicinal Chemistry Pharmaceutical ScienceMetabolic Hot SpotChemoprevention StrategyPharmacotherapyAmg 458	2008	94
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity Thomas A. Munro, Loren Berry, Ashlee Van’t Veer, BMC Pharmacology	2012	90
PHARMACOKINETICS AND METABOLISM OF [14C]EPLERENONE AFTER ORAL ADMINISTRATION TO HUMANS Chyung S. Cook, Loren Berry, Roy H. Bible, Drug Metabolism and Disposition	2003	89
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity Russell F. Graceffa, Alessandro A. Boezio, Jessica Able, Journal of Medicinal Chemistry	2017	66
Species Differences in Distribution and Prediction of Human Vss from Preclinical Data Loren Berry, Chao Li, Zhiyang Zhao Drug Metabolism and Disposition	2011	63
Involvement of CYP3A in the Metabolism of Eplerenone in Humans and Dogs: Differential Metabolism by CYP3A4 and CYP3A5 Chyung S. Cook, Loren Berry, David H. Kim, Drug Metabolism and Disposition	2002	62

Page 1